Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05821387 | Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers | PHASE1 | COMPLETED | 40 | — | — | Mar 22, 2023 | Jul 29, 2023 | Aug 29, 2023 | 1 | Canada |
Incidence and severity of adverse events (AEs), laboratory, ECG, physical exam, neurological exam and vital sign changes
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
| Arm | Type | Description |
|---|---|---|
| Lucid-21-302 | EXPERIMENTAL | Single-ascending dose cohorts |
| Placebo | PLACEBO_COMPARATOR | Single-ascending dose cohorts |
| Name | Type | Description |
|---|---|---|
| Lucid-21-302 | DRUG | A small molecule inhibitor of hypercitrullination |
| Placebo | DRUG | Product containing excipients with no active ingredients |
Inclusion Criteria: 1. Healthy male and female volunteers, 18 - 60 years of age, inclusive at the time of informed consent. 2. Body mass index (BMI) that is within 18.5 - 30.0 kg/m2, inclusive, and minimum weight of 50 kg. 3. Healthy, according to the medical history, ECG, vital signs, laboratory r...